Do not add any figures. Chapter 2 argues that plasminogen activator inhibitor-1, or PAI-1, is more than a fibrinolysis inhibitor. Instead, it acts as a central integrator linking lipid dysregulation, chronic inflammation, fibroblast dysfunction, and fibrosis. Fibroblasts are major producers of both PAI-1 and extracellular matrix. Under normal conditions, they support tissue repair through controlled matrix remodeling. However, chronic lipid and inflammatory stress can shift fibroblasts toward senescent, myofibroblast, and pro-fibrotic states. Elevated PAI-1 reinforces these changes by reducing plasmin-mediated matrix degradation, altering cell adhesion and migration, and promoting collagen accumulation. PAI-1 is regulated by multiple lipid classes rather than a single pathway. Membrane lipids such as cholesterol, sphingomyelin, and phospholipids organize lipid rafts that localize uPAR, integrins, and LRP1 and influence PAI-1 receptor signaling and endocytosis. Other lipids act through inflammatory and metabolic pathways. Glycerophospholipids and oxidized phospholipids can activate NF-κB and TLR signaling, while ceramide promotes PP2A and MAPK activity, reduces Akt signaling, stabilizes p53, and contributes to a ceramide–p53–PAI-1 axis that supports fibroblast senescence. Triglyceride excess also contributes to PAI-1 dysregulation. During obesity and insulin resistance, increased free fatty acids, ER stress, and oxidative stress stimulate PAI-1 production. This relationship can become bidirectional because elevated PAI-1 may impair VLDL clearance, further worsening lipid dysregulation. In contrast, omega-3 fatty acids and pro-resolving mediators can reduce inflammatory signaling and PAI-1 expression, while prenol lipids regulate Rho-family GTPases involved in inflammatory signaling and cytoskeletal organization. Immune cells further amplify these pathways. Lipid-stressed macrophages release inflammatory cytokines such as TNF-α, IL-1β, and IL-6, which stimulate PAI-1 production in fibroblasts and surrounding cells. Elevated PAI-1 then reduces extracellular matrix degradation and promotes inflammatory-cell retention, reinforcing chronic inflammation. Overall, the chapter proposes a self-amplifying lipid–PAI-1–fibroblast axis. Lipid dysregulation activates NF-κB, AP-1, SMAD, and p53 signaling, which increases PAI-1. Elevated PAI-1 then promotes fibroblast senescence, extracellular matrix accumulation, impaired tissue repair, and fibrosis. The central conclusion is that PAI-1 acts as an integrator of metabolic and inflammatory stress and represents a potential therapeutic target in chronic metabolic and fibrotic disease.
Do not add any figures.
Chapter 2 argues that plasminogen activator inhibitor-1, or PAI-1, is more than a fibrinolysis inhibitor. Instead, it acts as a central integrator linking lipid dysregulation, chronic inflammation, fibroblast dysfunction, and fibrosis.
Fibroblasts are major producers of both PAI-1 and extracellular matrix. Under normal conditions, they support tissue repair through controlled matrix remodeling. However, chronic lipid and inflammatory stress can shift fibroblasts toward senescent, myofibroblast, and pro-fibrotic states. Elevated PAI-1 reinforces these changes by reducing plasmin-mediated matrix degradation, altering cell adhesion and migration, and promoting collagen accumulation.
PAI-1 is regulated by multiple lipid classes rather than a single pathway. Membrane lipids such as cholesterol, sphingomyelin, and phospholipids organize lipid rafts that localize uPAR, integrins, and LRP1 and influence PAI-1 receptor signaling and endocytosis. Other lipids act through inflammatory and metabolic pathways. Glycerophospholipids and oxidized phospholipids can activate NF-κB and TLR signaling, while ceramide promotes PP2A and MAPK activity, reduces Akt signaling, stabilizes p53, and contributes to a ceramide–p53–PAI-1 axis that supports fibroblast senescence.
Triglyceride excess also contributes to PAI-1 dysregulation. During obesity and insulin resistance, increased free fatty acids, ER stress, and oxidative stress stimulate PAI-1 production. This relationship can become bidirectional because elevated PAI-1 may impair VLDL clearance, further worsening lipid dysregulation. In contrast, omega-3 fatty acids and pro-resolving mediators can reduce inflammatory signaling and PAI-1 expression, while prenol lipids regulate Rho-family GTPases involved in inflammatory signaling and cytoskeletal organization.
Immune cells further amplify these pathways. Lipid-stressed macrophages release inflammatory cytokines such as TNF-α, IL-1β, and IL-6, which stimulate PAI-1 production in fibroblasts and surrounding cells. Elevated PAI-1 then reduces extracellular matrix degradation and promotes inflammatory-cell retention, reinforcing chronic inflammation.
Overall, the chapter proposes a self-amplifying lipid–PAI-1–fibroblast axis. Lipid dysregulation activates NF-κB, AP-1, SMAD, and p53 signaling, which increases PAI-1. Elevated PAI-1 then promotes fibroblast senescence, extracellular matrix accumulation, impaired tissue repair, and fibrosis. The central conclusion is that PAI-1 acts as an integrator of metabolic and inflammatory stress and represents a potential therapeutic target in chronic metabolic and fibrotic disease.
Created using ChatSlide
This presentation explores the role of PAI-1 in reframing fibrosis as a metabolic disorder. It discusses how PAI-1 integrates stress signals, influencing fibroblast behavior in tissue repair and matrix turnover. Additionally, it defines the lipid–PAI-1–fibroblast axis, highlighting how lipids activate inflammatory pathways and how PAI-1 inhibits matrix breakdown, leading to fibroblast senescence and myofibroblast states. This comprehensive overview aims to enhance understanding of the...